A review of onabotulinumtoxinA (Botox).

Z. Paul Lorenc, Jeffrey M. Kenkel, Steven Fagien, Haideh Hirmand, Mark S. Nestor, Anthony P. Sclafani, Jonathan M Sykes, Heidi A. Waldorf

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

OnabotulinumtoxinA was introduced to the US market in 2002 as the first botulinum toxin type A (BoNTA) approved for facial aesthetics. This article provides an overview of onabotulinumtoxinA's uses and indications as well as safety and efficacy data. As with other BoNTA products, onabotulinumtoxinA is generally well tolerated. Consideration is also given to clinical applications of the product. Information on handling, storage, and dosing is provided.

Original languageEnglish (US)
JournalAesthetic surgery journal / the American Society for Aesthetic Plastic surgery
Volume33
Issue number1 Suppl
DOIs
StatePublished - Mar 2013
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lorenc, Z. P., Kenkel, J. M., Fagien, S., Hirmand, H., Nestor, M. S., Sclafani, A. P., Sykes, J. M., & Waldorf, H. A. (2013). A review of onabotulinumtoxinA (Botox). Aesthetic surgery journal / the American Society for Aesthetic Plastic surgery, 33(1 Suppl). https://doi.org/10.1177/1090820X12474629